Published in Int J Chron Obstruct Pulmon Dis on August 01, 2016
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl (1993) 20.55
A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 17.19
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA (1994) 10.46
American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med (2003) 3.59
Guidelines for the measurement of respiratory function. Recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. Respir Med (1994) 2.49
Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD (2009) 2.41
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res (2009) 2.31
Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med (2006) 2.20
A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med (1999) 1.99
Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease. Thorax (1996) 1.94
Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study. J Clin Epidemiol (1988) 1.89
Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet (2015) 1.87
Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest (2001) 1.84
High-resolution computed tomography scanning in alpha1-antitrypsin deficiency: relationship to lung function and health status. Eur Respir J (2001) 1.71
Rate of progression of lung function impairment in alpha1-antitrypsin deficiency. Eur Respir J (2009) 1.61
Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med (2004) 1.43
Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J (2009) 1.41
Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med (1998) 1.40
Respiratory risk factors and mortality: longitudinal studies in Washington County, Maryland. Am Rev Respir Dis (1989) 1.38
Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis (2012) 1.35
Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency. Thorax (2006) 1.24
Predictors of mortality in alpha1-antitrypsin deficiency. Thorax (2003) 1.24
Progression parameters for emphysema: a clinical investigation. Respir Med (2007) 1.22
Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med (2014) 1.20
Interpreting periodic lung function tests in individuals: the relationship between 1- to 5-year and long-term FEV1 changes. Chest (2006) 1.04
Detection of emphysema progression in alpha 1-antitrypsin deficiency using CT densitometry; methodological advances. Respir Res (2008) 0.93
Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis (2013) 0.85
Relationship of the 2011 Global Initiative for Chronic Obstructive Lung Disease strategy to clinically relevant outcomes in individuals with α1-antitrypsin deficiency. Ann Am Thorac Soc (2014) 0.78
Lung density associates with survival in alpha 1 antitrypsin deficient patients. Respir Med (2016) 0.78
Relationship between Change in Lung Density and Long-Term Progression of Lung Function. Am J Respir Crit Care Med (2015) 0.76